Martijn Brouwers

Professor

Dr Martijn Brouwers obtained his MD degree (with honours) in 2002, after which he started his PhD project that focused on hepatic steatosis in familial combined hyperlipidemia. In 2006, he worked as a trainee at the Department of Internal Medicine and Endocrinology. Since 2012, he has been a staff member (internist-endocrinologist) at Maastricht UMC+ and in 2019 he was appointed as the head of the division of Endocrinology and Metabolic Disease and in 2025 as leader of the Division Vessels within CARIM. He is the scientific director of The Maastricht Study.  

His research focusses on the cardiometabolic consequences of metabolic dysfunction-associated steatotic liver disease (MASLD), and the role of fructose herein. MASLD consists of a histological spectrum comprising simple steatosis, steatohepatitis, fibrosis and cirrhosis. Evidence is accumulating that MASLD is not only a liver disease per se, it is also a risk factor for type 2 diabetes, chronic kidney disease, poly-endocrine metabolic ovarian syndrome (PMOS, formerly known as PCOS) and cardiovascular disease. This research line aims to elucidate the exact mechanistic link between MASLD and these systemic diseases, and how different sources of dietary fructose affect MASLD and its sequaelae. For this, a diverse set of studies is used, ranging from (genetic) epidemiology, to ‘human knockout’ models, to randomised controlled trials and experimental animal work. This research is in part funded by the Dutch Heart Foundation, the Dutch Diabetes Foundation and the European Foundation for the Study of Diabetes.

Department ofInternal Medicine
P. Debeyelaan 25, 6229 HX Maastricht 
PO Box 5800, 6202 AZ Maastricht
T: +31(0)43 388 70 19

  • 2016
    • van Dalem, J., Brouwers, M. C. G. J., Stehouwer, C. D. A., Krings, A., Leufkens, H. G. M., Driessen, J. H. M., de Vries, F., & Burden, A. M. (2016). Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study. BMJ, 354, Article i3625. https://doi.org/10.1136/bmj.i3625
    • Jahja, R., van Spronsen, F. J., de Sonneville, L. M. J., van der Meere, J. J., Bosch, A. M., Hollak, C. E. M., Rubio Gozalbo, E., Brouwers, M. C. G. J., Hofstede, F. C., de Vries, M. C., Janssen, M. C. H., van der Ploeg, A. T., Langendonk, J. G., & Huijbregts, S. C. J. (2016). Social-cognitive functioning and social skills in patients with early treated phenylketonuria: a PKU-COBESO study. Journal of Inherited Metabolic Disease, 39(3), 355-362. https://doi.org/10.1007/s10545-016-9918-0
    • Hollak, C. E. M., Biegstraaten, M., Baumgartner, M. R., Belmatoug, N., Bembi, B., Bosch, A., Brouwers, M., Dekker, H., Dobbelaere, D., Engelen, M., Groenendijk, M. C., Lachmann, R., Langendonk, J. G., Langeveld, M., Linthorst, G., Morava, E., Poll-The, B. T., Rahman, S., Rubio Gozalbo, E., ... Hagendijk, R. (2016). Position statement on the role of healthcare professionals, patient organizations and industry in European Reference Networks. Orphanet Journal of Rare Diseases, 11(1), Article 7. https://doi.org/10.1186/s13023-016-0383-5
    • van Dalem, J., Brouwers, M., Stehouwer, C., Krings, A., Leufkens, H. G. M., Driessen, J. H. M., de Vries, F., & Burden, A. (2016). Het risico op hypoglykemieën bij sulfonylureumderivaten ten opzichte van metformine in relatie tot nierfunctie en metabolietgroep. Nederlands Platform voor Farmaceutisch Onderzoek, 1, Article a1636. https://www.knmp.nl/professie/wetenschap/nederlands-platform-voor-farmaceutisch-onderzoek/het-risico-op-hypoglykemieen-bij-sulfonylureumderivaten-ten-opzichte-van-metformine-in-relatie-tot-nierfunctie-en-metabolietgroep
  • 2015
    • Brouwers, M. C. G. J. (2015). Electrolyte and Acid-Base Disturbances in Diabetes Mellitus. New England Journal of Medicine, 373(25), 2482-2482.
    • Liemburg, G. B., Jahja, R., van Spronsen, F. J., de Sonneville, L. M. J., van der Meere, J. J., Bosch, A. M., Hollak, C. E. M., Rubio-Gozalbo, M. E., Brouwers, M. C. G. J., Hofstede, F. C., de Vries, M. C., Janssen, M. C. H., van der Ploeg, A. T., Langendonk, J. G., & Huijbregts, S. C. J. (2015). Is BRIEF a useful instrument in day to day care of patients with phenylketonuria?Molecular Genetics and Metabolism, 114(3), 425-430. https://doi.org/10.1016/j.ymgme.2014.12.302
    • Brouwers, M. C. G. J., Ham, J. C., Wisse, E., Misra, S., Cleuren - Landewe, S., Rosenthal, M., Patel, D., Oliver, N., Bilo, H. J. G., & Murphy, E. (2015). Elevated Lactate Levels in Patients With Poorly Regulated Type 1 Diabetes and Glycogenic Hepatopathy: A New Feature of Mauriac Syndrome. Diabetes Care, 38(2), E11-E12. https://doi.org/10.2337/dc14-2205
    • Brouwers, M. C. G. J., Jacobs, C., Bast, A., Stehouwer, C. D. A., & Schaper, N. C. (2015). Modulation of Glucokinase Regulatory Protein: A Double-Edged Sword?Trends in Molecular Medicine, 21(10), 583-594. https://doi.org/10.1016/j.molmed.2015.08.004
  • 2014
    • van Greevenbroek, M. M. J., Stalenhoef, A. F. H., de Graaf, J., & Brouwers, M. C. G. J. (2014). Familial combined hyperlipidemia: from molecular insights to tailored therapy. Current Opinion in Lipidology, 25(3), 176-182. https://doi.org/10.1097/MOL.0000000000000068
    • Brouwers, M. C. G. J., van Greevenbroek, M. M. J., Konrad, R. J., Troutt, J. S., Schaper, N. C., & Stehouwer, C. D. A. (2014). Circulating PCSK9 is a strong determinant of plasma triacylglycerols and total cholesterol in homozygous carriers of apolipoprotein ε2. Clinical Science, 126(9), 679-684. https://doi.org/10.1042/CS20130556
  • 2013
    • Brouwers, M. C. G. J., Konrad, R. J., van Himbergen, T. M., Isaacs, A., Otokozawa, S., Troutt, J. S., Schaefer, E. J., van Greevenbroek, M. M. J., Stalenhoef, A. F. H., & de Graaf, J. (2013). Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia. Nutrition Metabolism and Cardiovascular Diseases, 23(11), 1115-1121. https://doi.org/10.1016/j.numecd.2012.11.008
    • Jahja, R., Huijbregts, S. C. J., de Sonneville, L. M. J., van der Meere, J. J., Bosch, A. M., Hollak, C. E. M., Rubio-Gozalbo, M. E., Brouwers, M. C. G. J., Hofstede, F. C., de Vries, M. C., Janssen, M. C. H., van der Ploeg, A. T., Langendonk, J. G., & van Spronsen, F. J. (2013). Mental health and social functioning in early treated Phenylketonuria: The PKU-COBESO study. Molecular Genetics and Metabolism, 110(SUPPL.), S57-S61. https://doi.org/10.1016/j.ymgme.2013.10.011
  • 2012
    • van Greevenbroek, M. M. J., Ghosh, S., van der Kallen, C. J. H., Brouwers, M. C. G. J., Schalkwijk, C. G., & Stehouwer, C. D. A. (2012). Up-Regulation of the Complement System in Subcutaneous Adipocytes from Nonobese, Hypertriglyceridemic Subjects Is Associated with Adipocyte Insulin Resistance. Journal of Clinical Endocrinology & Metabolism, 97(12), 4742-4752. https://doi.org/10.1210/jc.2012-2539
    • van Sloten, T. T., Pijpers, E., Stehouwer, C. D. A., & Brouwers, M. C. (2012). Metformin-associated lactic acidosis in a patient with normal kidney function.Diabetes Research and Clinical Practice, 96(3), E57-E58. https://doi.org/10.1016/j.diabres.2011.07.021
    • Brouwers, M. C. G. J., van Greevenbroek, M. M. J., Stehouwer, C. D. A., de Graaf, J., & Stalenhoef, A. F. H. (2012). The genetics of familial combined hyperlipidaemia. Nature Reviews Endocrinology, 8(6), 352-362. https://doi.org/10.1038/nrendo.2012.15
  • 2011
    • Brouwers, M. C., van Greevenbroek, M. M. J., Troutt, J., Bonner Freeman, A., Lu, A., Schaper, N. C., Konrad, R. J., & Stehouwer, C. D. A. (2011). Plasma proprotein convertase subtilisin kexin type 9 is a heritable trait of familial combined hyperlipidemia. Clinical Science, 121(9), 397-403. https://doi.org/10.1042/CS20110129
    • Brouwers, M. C., Troutt, J. S., van Greevenbroek, M. M. J., Ferreira, I., Feskens, E. J., van der Kallen, C. J. H., Schaper, N. C., Schalkwijk, C. G., Konrad, R. J., & Stehouwer, C. D. A. (2011). Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: The CODAM study. Atherosclerosis, 217(1), 263-267. https://doi.org/10.1016/j.atherosclerosis.2011.03.023
  • 2010
  • 2009
    • Brouwers, M. C., Reesink, K. D., van Greevenbroek, M. M., Meinders, J. M., van der Kallen, C. J., Schaper, N., Hoeks, A. P., & Stehouwer, C. D. (2009). Increased arterial stiffness in familial combined hyperlipidemia. Journal of Hypertension, 27(5), 1009-16. https://doi.org/10.1097/HJH.0b013e32832991fa
  • 2008
    • Brouwers, M. C., Dekker, J. M., van Greevenbroek, M. M., van der Kallen, C. J., Heine, R. J., de Bruin, T. W., & Stehouwer, C. D. (2008). Plasma triglycerides and LDL cholesterol are related in a parabolic fashion in the general population and patients with Type 2 diabetes mellitus: long-term follow-up results from the Hoorn study. Diabetic Medicine, 25(9), 1121-4. https://doi.org/10.1111/j.1464-5491.2008.02524.x
  • 2007
    • Wang, P., van Greevenbroek, M. M., Bouwman, F. G., Brouwers, M. C., van der Kallen, C. J. H., Smit, E., Keijer, J., & Mariman, E. C. (2007). The circulating PBEF/NAMPT/visfatin level is associated with a beneficial blood lipid profile. Pflugers Archiv-European Journal of Physiology, 454(6), 971-976. https://doi.org/10.1007/s00424-007-0262-y